Pharma's Almanac TV
PA TV
Your Name
Your Email
Manage Account
Dashboard
Sign Out
Sign In
Register
Topics
Products
ADC
API - Small Molecule
Biologics
Biopharmaceuticals
Biosimilars
Cell and Gene Therapy
DNA
Drug Product
Drug Substance
Equipment
Generics
Immunotherapy
Injectables
Monoclonal Antibody
Novel Therapeutics
Oral Solid Dosage
Orphan Drugs
Parenterals
Stem Cells
Vaccine
Services
Big Data
Bioprocessing
Clinical Trials
Continuous Manufacturing
Diagnostics
Drug Delivery
Drug Development
Drug Discovery
Facility
Formulation
Innovation
Oncology
Patient Adherence
Patient Centric
Preclinical
Process Development
Quality
Regulatory
Research
Serialization
Segment
Biomanufacturing
Biotechnology
CDMO
Consulting
CRO
Engineering
Equipment
Excipients
Healthcare
Intermediates
Logistics
Manufacturing
Packaging
Supply Chain
Business
Agreement
Appointment
Business
Capacity Expansion
Collaboration
Growth
Investment
Licensing
M&A
Market Expansion
Market Intelligence
Market Prediction
New Facility
Strategic Partnership
Analytics
Research
CDMO
CRO
Excipients
Pharmaceutical Equipment
Pharmaceutical Intermediates
Supply Chain Logistics
Magazine
Current Issue
Archive
Community
Company A to Z
Content Filter
More+
Staffing
Media Kit
Membership Levels
By The Numbers
Oncology
263 Articles Available
1
11
Can't find what you're looking for? Try our
advanced search
.
Endpoint
Array Biopharma Announces Braftovi + Mektovi + Cetuximab Meet Primary Endpoints in Metastatic Colorectal Cancer
PR-M05-19-NI-069
M&A
Merck to Acquire Peloton Therapeutics, Bolstering Oncology Pipeline
PR-M05-19-NI-067
Phase I Study
Painting Tumors Is a Promising Approach to Improve Surgical Outcomes
PAO-M05-19-NI-024
FDA Approval
Genentech Announces FDA Approval for Venclexta Plus Gazyva for People With Previously Untreated Chronic Lymphocytic Leukemia
PR-M05-19-NI-050
Oncology
Apollo Proton Cancer Centre, Chennai performs India's First Total Marrow Irradiation Procedure
Oncology
LabCorp Announces Availability of New QIAGEN therascreen FGFR mutation analysis companion diagnostic for Bladder Cancer
PR-M05-19-NI-042
Oncology
FDA Will Use Real-Time Oncology Review for Prostate Cancer Drug
PAO-M05-19-NI-012
Collaboration
Amgen And Syapse Enter Precision Medicine Collaboration In Oncology
PR-M05-19-NI-014
Drug Development
Lung Cancer Drug Demonstrates Improved Survival in Animal Models
PAO-M05-19-NI-003
Drug Development
Janssen Submits Application to U.S. FDA Seeking Approval of ERLEADA® (apalutamide) for Patients with Metastatic Castration-Sensitive Prostate Cance
PR-M05-19-NI-001
Positive Opinion
Pfizer Receives Positive CHMP Opinion for TALZENNA®(talazoparib) for Patients with Inherited (Germline) BRCA-Mutated Locally Advanced or Metastatic Breast Cancer
PR-M04-19-NI-086
Trial Update
Merck Provides Update on Phase 3 KEYNOTE-062 Trial
PR-M04-19-NI-085
Oncology
New Publication Validates Clinical Performance of Signatera for Recurrence Monitoring and MRD Assessment in Breast Cancer
PR-M04-19-NI-062
FDA Approval
J&J’s Bladder Cancer Drug Gets Accelerated FDA Approval
PAO-M04-19-NI-019
FDA Approval
FDA Approves First Targeted Therapy for Metastatic Bladder Cancer
PR-M04-19-NI-050
Oncology
Bayer Announces Results of Sub-group Analysis for Vitrakvi® (larotrectinib) in Patients with NTRK Gene Fusion-Positive Metastatic Non-small Cell Lung Cancer (NSCLC)
PR-M04-19-NI-047
Allogeneic CAR-T
FDA Clears the IND for UCARTCS1, the First Allogeneic CAR-T to Treat Multiple Myeloma Patients
PR-M04-19-NI-028
Drug Target
Caris Life Sciences Identifies a Splicing Complex on the Surface of Non-Hodgkin's Lymphoma Cells that Is a Potential Anti-Tumor Drug Target
PR-M04-19-NI-003
Drug Development
New Blood Cancer Drug Shows Promise
PAO-M03-19-NI-039
Fertility
A New Approach to Preserving Fertility for Cancer Patients?
PAO-M03-19-NI-036
Oncology
New Tech Could Provide Early Detection of Tumors
PAO-M03-19-NI-035
Investment
Portage Makes Additional Investment in Stimunity S.A, a Paris-based Cancer Immunotherapy Company
PR-M03-19-NI-081
Enpoint
Lilly's CYRAMZA® Phase 3 RELAY Trial Met Primary Endpoint in First-Line Treatment of Patients with Metastatic EGFR-Mutated Non-Small Cell Lung Cancer
PR-M03-19-NI-039
Approval
European Commission Approved Tecentriq/Avastin Combination Therapy for Lung Cancer
PAO-M03-19-NI-018
1
11
»
